UPI: Promising pancreatic cancer treatment

Media highlights potential new cancer therapy that could be in clinical trials soon

A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans, according to University of Cincinnati researchers.

The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously difficult to treat.

"Based on pre-clinical studies, it has the potential to improve pancreatic cancer treatment," Xiaoyang Qi, PhD, a professor of hematology oncology at the University of Cincinnati College of Medicine and member of the UC Cancer Center. Qi is a lead author on the study which was published in the academic journal Molecular Therapy.

Read the full story.

Read the UC news release.

The Cincinnati Enquirer also covered this research.

Featured photo of pancreatic cancer cells courtesy of National Institutes of Health. Credit/Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

1

'My health is priceless'

April 7, 2026

Weight loss drugs, including Ozempic and Wegovy, are changing more than waistlines — they're quietly transforming how people spend money, what they prioritize and who can afford better health. As Local 12/WKRC-TV recently reported, for some patients, the medications are life-changing. For others, the cost can be overwhelming.

2

Students prefer AI chatbots, until they know it is one

April 7, 2026

A University of Cincinnati College of Nursing pilot study found that Doctor of Nursing Practice students preferred AI chatbot responses over human answers — until they suspected the source was a chatbot, revealing trust issues in higher education advising.